MedTrace Logo

Beta-1,3/1,6-D-Glucan Ganoderma Lucidum on Ulcerative Colitis

NCT04029649 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2019-08-02

No results posted yet for this study

Summary

The aim of this study is to determine the efficacy and safety of Beta-1,3/1,6-D-Glucan from mycelium extract of Ganoderma lucidum on ulcerative colitis

Conditions

Interventions

DRUG

Beta-1,3/1,6-D-Glucan

Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days

DRUG

Placebo

Placebo capsule three times daily for 90 days

Sponsors & Collaborators

  • Fakultas Kedokteran Universitas Indonesia

    lead OTHER

Principal Investigators

  • Marcellus Simadibrata · Division Of Gastroenterology Department Of Internal Medicine Faculty Of Medicine Universitas Indonesia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04029649 on ClinicalTrials.gov